How many drugs treat Osteoarthritis?

Drug Landscape tracks 10 marketed treatments for Osteoarthritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/osteoarthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osteoarthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteoarthritis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteoarthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Loqoa	ESFLURBIPROFEN	Taisho Pharmaceutical Co., Ltd.		Prostaglandin G/H synthase 2	2015-01-01
Joicela	LUMIRACOXIB	Novartis Pharmaceuticals UK Limited	lumiracoxib	Prostaglandin G/H synthase 1	2005-01-01
Mobic	MELOXICAM	Boehringer Ingelheim	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2000-01-01
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Daypro	Oxaprozin	Solubiomix	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1	1992-01-01
Lodine	ETODOLAC	Pfizer	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	1991-01-01
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01
Ocufen	flurbiprofen	Pfizer	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 1	1986-01-01
Feldene	PIROXICAM	Pfizer	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 1	1982-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 17 drugs in Osteoarthritis
Pfizer · 4 drugs in Osteoarthritis
Boehringer Ingelheim · 1 drug in Osteoarthritis
CrystalGenomics · 1 drug in Osteoarthritis
Eli Lilly · 1 drug in Osteoarthritis
Endo · 1 drug in Osteoarthritis
Generic (multiple manufacturers) · 1 drug in Osteoarthritis
Generic (originally Boots Group) · 1 drug in Osteoarthritis
Generic (originally Syntex) · 1 drug in Osteoarthritis
HengRui · 1 drug in Osteoarthritis
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Osteoarthritis
Janssen · 1 drug in Osteoarthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteoarthritis:

Cite this brief

Drug Landscape (2026). Osteoarthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteoarthritis. Accessed 2026-06-10.

Osteoarthritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing